Biologics distributors differ in how much documentation they maintain and how readily they share it. A qualification review should include establishment registration status, donor eligibility determination records, and the certificate of analysis for the specific lot being purchased, not just a general product sheet. For Wharton's jelly allografts, qualification also means asking how the supplier describes its HCT/P framework. Whether a specific intended use meets all applicable criteria in 21 CFR 1271.10 is a determination for the clinic and its counsel, not a sales conversation.
For cord blood or umbilical cord-derived exosome products, qualification looks different. FDA states that no exosome product currently carries FDA approval, and these products are generally regulated as biologic drugs under section 351 of the Public Health Service Act. Purchase and clinical-use decisions for these products belong to the physician, working with their own regulatory counsel, not to the supplier. A clinic evaluating an exosome supplier should still expect a full ingredient disclosure and particle characterization data, such as nanoparticle tracking analysis or tetraspanin marker results. A supplier unwilling to produce this documentation, or unable to explain its testing method, has not been qualified.
Vendor qualification is the review completed before selecting a supplier. A separate, periodic supplier audit checks whether that supplier's practices still match its documentation after the relationship begins. FDA has treated a distributor's website, affiliate content and social media as evidence of a product's intended use, so a clinic should still note any shift in how a supplier markets its own products when it revisits a supplier list. Keep the qualification file with relevant lot documentation for internal review.
A qualification file records what the clinic reviewed before selecting a supplier.